Entera Bio Ltd. (ENTX)
2.84
-0.17
(-5.65%)
USD |
NASDAQ |
Sep 09, 16:00
2.86
+0.02
(+0.70%)
After-Hours: 18:10
Entera Bio Enterprise Value : 130.36M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 130.36M |
| September 04, 2026 | 129.86M |
| September 03, 2026 | 127.40M |
| September 02, 2026 | 125.92M |
| September 01, 2026 | 124.94M |
| August 31, 2026 | 127.40M |
| August 28, 2026 | 131.34M |
| August 27, 2026 | 133.81M |
| August 26, 2026 | 139.23M |
| August 25, 2026 | 153.03M |
| August 24, 2026 | 150.57M |
| August 21, 2026 | 141.20M |
| August 20, 2026 | 140.71M |
| August 19, 2026 | 135.29M |
| August 18, 2026 | 124.44M |
| August 17, 2026 | 124.94M |
| August 14, 2026 | 124.44M |
| August 13, 2026 | 123.46M |
| August 12, 2026 | 120.01M |
| August 11, 2026 | 129.86M |
| August 10, 2026 | 131.84M |
| August 07, 2026 | 123.46M |
| August 06, 2026 | 120.99M |
| August 05, 2026 | 120.50M |
| August 04, 2026 | 123.46M |
| Date | Value |
|---|---|
| August 03, 2026 | 127.89M |
| July 31, 2026 | 129.37M |
| July 30, 2026 | 127.40M |
| July 29, 2026 | 129.86M |
| July 28, 2026 | 142.68M |
| July 27, 2026 | 175.21M |
| July 24, 2026 | 83.04M |
| July 23, 2026 | 86.98M |
| July 22, 2026 | 82.05M |
| July 21, 2026 | 78.60M |
| July 20, 2026 | 80.08M |
| July 17, 2026 | 79.59M |
| July 16, 2026 | 80.57M |
| July 15, 2026 | 69.73M |
| July 14, 2026 | 61.84M |
| July 13, 2026 | 62.83M |
| July 10, 2026 | 63.57M |
| July 09, 2026 | 65.79M |
| July 08, 2026 | 65.29M |
| July 07, 2026 | 63.82M |
| July 06, 2026 | 66.28M |
| July 02, 2026 | 63.82M |
| July 01, 2026 | 65.29M |
| June 30, 2026 | 69.24M |
| June 29, 2026 | 65.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 9.026M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 419.95M |
| Can-Fite BioPharma Ltd. | -3.976M |
| Galmed Pharmaceuticals Ltd. | -7.431M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.312M |
| Total Expenses (Quarterly) | 7.312M |
| EPS Diluted (Quarterly) | -0.1449 |
| Earnings Yield | -12.38% |
| Normalized Earnings Yield | -12.38 |